2022
DOI: 10.1016/j.shj.2022.100072
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Impella 5.5 on Preexisting Functional Mitral Regurgitation in Patients with Heart Failure–Related Cardiogenic Shock

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(4 citation statements)
references
References 18 publications
0
4
0
Order By: Relevance
“…In a recent study evaluating the impact of Impella 5.5 hemodynamics on patients with moderate to severe functional mitral regurgitation, Kataria and colleagues found that Impella 5.5 improved hemodynamic response 24 h postimplant with increased cardiac index and decreased CVP, dPAP, and systemic vascular resistance. 17 There was also a significant decrease in serum lactate, and although nonsignificant, all other laboratory values (serum creatinine, alanine aminotransferase, aspartate aminotransferase, and bilirubin) showed improvement after 24 h on Impella 5.5. In the present study, hemodynamic and laboratory data were similar between the prolonged and short-term cohorts on POD1 and POD5, and at the time of explant, and there was a trend toward improved hemodynamics and laboratory values in the prolonged cohort.…”
Section: Discussionmentioning
confidence: 81%
“…In a recent study evaluating the impact of Impella 5.5 hemodynamics on patients with moderate to severe functional mitral regurgitation, Kataria and colleagues found that Impella 5.5 improved hemodynamic response 24 h postimplant with increased cardiac index and decreased CVP, dPAP, and systemic vascular resistance. 17 There was also a significant decrease in serum lactate, and although nonsignificant, all other laboratory values (serum creatinine, alanine aminotransferase, aspartate aminotransferase, and bilirubin) showed improvement after 24 h on Impella 5.5. In the present study, hemodynamic and laboratory data were similar between the prolonged and short-term cohorts on POD1 and POD5, and at the time of explant, and there was a trend toward improved hemodynamics and laboratory values in the prolonged cohort.…”
Section: Discussionmentioning
confidence: 81%
“…Kataria et al . 9 reported 24 patients with functional mitral regurgitation treated with Impella 5.5. Salas De Armas et al .…”
Section: Resultsmentioning
confidence: 99%
“…Five studies described selected populations treated with Impella devices. Kataria et al 9 reported 24 patients with functional mitral regurgitation treated with Impella 5.5. Salas De Armas et al 15 reported eight patients with refractory hemolysis on Impella CP support who were upgraded to Impella 5.0 or 5.5.…”
Section: Baseline Characteristicsmentioning
confidence: 99%
“…Care was later withdrawn due to inability to wean from mechanical support [47]. Kataria and colleagues described three cases of successful use of ProtekDuo® for acute right heart failure in patients with Impella 5.5 placed for heart failure-related cardiogenic shock, though specific outcomes of these patients were not discussed [48]. See Figure 3.…”
Section: Protekduo® With Temporary Lvadsmentioning
confidence: 99%